{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:09Z","timestamp":1793727789766,"version":"4.6.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40264-019-00899-y","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T17:45:25Z","timestamp":1580838325000},"page":"351-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase\u00ae"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-6084","authenticated-orcid":false,"given":"Ulrich","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"van Stekelenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hosain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"6","key":"899_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"key":"899_CR2","unstructured":"EFPIA. Report to the EMA: Joint industry position paper on current challenges and experiences with signal detection in EudraVigilance with proposal for the future. Brussels (Be): EFPIA Pharmacovigilance Expert Group. 2019."},{"key":"899_CR3","unstructured":"Kane SP. ClinCalc DrugStats Database, version 19.1. ClinCalc. 2019. https:\/\/clincalc.com\/DrugStats. Updated 24 Nov 2018. Accessed 11 June 2019."},{"key":"899_CR4","unstructured":"European Medicines Agency. EudraVigilance. 2019. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 12 Nov 2019."},{"key":"899_CR5","unstructured":"European Medicines Agency. Inspections, human medicine, pharmacovigilance and committees division. screening for adverse reactions in EudraVigilance. EMA\/849944\/2016. London: EMA; 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf. Accessed 12 Nov 2019."},{"key":"899_CR6","unstructured":"European Medicines Agency. EudraVigilance User Manual. European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/eudravigilance-user-manual-marketing-authorisation-holders_en.pdf. Accessed 25 Nov 2019."},{"key":"899_CR7","unstructured":"European Medicines Agency. Important medical event terms list (MedDRA version 22.1). Internet document: 16 Sep 2019. 2019. https:\/\/www.ema.europa.eu\/en."},{"issue":"12","key":"899_CR8","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1109\/TVCG.2011.185","volume":"17","author":"M Bostock","year":"2011","unstructured":"Bostock M, Ogievetsky V, Heer J. D3: data-driven documents. IEEE Trans Visual Comput Graph.\u00a02011;17(12):2301\u20139.","journal-title":"IEEE Trans Visual Comput Graph"},{"key":"899_CR9","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https:\/\/www.r-project.org\/."},{"key":"899_CR10","doi-asserted-by":"publisher","first-page":"k714","DOI":"10.1136\/bmj.k714","volume":"360","author":"B Casassus","year":"2018","unstructured":"Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ. 2018;360:k714.","journal-title":"BMJ"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00899-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:42:39Z","timestamp":1612312959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00899-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00899-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"4 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ulrich Vogel is an employee of Boehringer Ingelheim International GmbH; John van Stekelenborg is an employee of Janssen, the Pharmaceutical Companies of Johnson & Johnson; Brian Dreyfus is an employee of Bristol-Myers Squibb Company; Anju Garg is an employee of Sanofi; Marian Habib is an employee of Allergan; Romana Hosain is an employee and shareholder of Regeneron; and Antoni Wisniewski is an employee and shareholder of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}